News | November 14, 2024
AbbVie provides update on Phase 2 results for Emraclidine in schizophrenia
Emraclidine was well-tolerated with an adverse event profile consistent with Phase 1b trial
Emraclidine was well-tolerated with an adverse event profile consistent with Phase 1b trial
Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophrenia
Subscribe To Our Newsletter & Stay Updated
